Non-Hodgkin Lymphoma Archives - Page 3 of 11

Over half of evaluable patients who received an infusion of tisagenlecleucel achieved response.

ASH 2020

Racial and Ethnic Minority Groups Had Worse Disease-Related Survival in Indolent NHL Compared With White Patients

By

Leah Lawrence

December 6, 2020

More research need to understand the reasons for survival differences.

Hematologic Cancers

Postmarketing Observational Study of Tisagenlecleucel for ALL or NHL Yields Promising Results

By

Susan Moench, PhD, PA-C

November 24, 2020

Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.

Small studies, the absence of subtypes, and a historical lack of genetic information has stopped past studies from triggering meaningful public health change, a review asserts.

Lymphoma

Why It’s Been So Hard to Conclusively Link Environmental Factors to Non-Hodgkin Lymphoma

By

Julia Faith Sklar

October 27, 2020

Small studies, the absence of subtypes, and a historical lack of genetic information has stopped past studies from triggering meaningful public health change, a review asserts.

Lymphoma

Pregnant Patients With Non-Hodgkin Lymphoma May Receive Chemotherapy

By

Patricia Chaney

October 15, 2020

Pregnant patients with non-Hodgkin lymphoma may be able to receive CHOP-like chemotherapy during pregnancy with some risks.

Lymphoma

Maternal, Fetal Considerations for the Treatment and Management of Lymphoma During Pregnancy

By

Jessica Nye, PhD

October 13, 2020

Although 1 in 1000 lymphoma diagnoses occurs in pregnancy, literature on best practices for treatment in this patient group is limited.

Lymphoma

Obinutuzumab With Cytarabine Induction for Transplant-Eligible Mantle Cell Lymphoma

By

Vicki Moore, PhD

October 9, 2020

In a phase 2 trial, obinutuzumab added to induction therapy showed promising activity and tolerability for transplant-eligible mantle cell lymphoma.

ROPETAR failed to demonstrate any clinical benefit in alternating treatment with pazopanib and evero

Lymphoma

Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations

By

Lauren Dembeck, PhD

September 17, 2020

Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.

A patient discusses a new oral medication regimen.

Hematologic Cancers

Waldenström Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow-Up

By

Lauren Dembeck, PhD

September 10, 2020

Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.

Lymphoma

2021 Update on Diagnosis, Risk Stratification, and Management of Cutaneous B-Cell Lymphomas

By

Rita Aghjayan

September 9, 2020

Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.

Association Between Cabozantinib and Skin Reactions in Patients with Urothelial Carcinoma

Lymphoma

Managing Skin Flare Reactions in Patients Receiving Mogamulizumab for Cutaneous T-cell Lymphoma

By

Susan Moench, PhD, PA-C

September 9, 2020

Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.